Investment
Features
FeesSafety
Academy
More
Pluang+

Compare MasterCard Inc (MA) vs Novavax Inc (NVAX) Price & Performance

MasterCard IncTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

MasterCard Inc vs Novavax Inc — how do they compare? MasterCard Inc trades at $559.19 (market cap $491.83B), while Novavax Inc trades at $7.97 (market cap $1.31B). The key difference: MasterCard Inc is far larger — about 375.4× Novavax Inc's market cap, and MasterCard Inc pays a 0.62% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.

MANVAX
Market Cap
$491.83B$1.31B
Volume
4,635,698
Sector
Consumer CyclicalHealth
52-Week High
$598.96$11.19
52-Week Low
$471.55$6.22
Enterprise Value
$504.86B$889.30M
Dividend Yield
0.62%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

MasterCard Inc

Mastercard (MA) trades at $563.17, up 0.04% today, with a bullish technical signal and strong institutional buying. The stock shows robust fundamentals, with revenue growing from $22.2B in 2022 to $32.8B in 2025 and net income margins above 45%. Recent earnings beats and a consensus price target of $660.85 reflect optimism, though high valuation ratios like a P/E of 30.98 warrant caution.

Outlook is positive due to consistent earnings growth, expanding digital payment initiatives, and analyst buy ratings. Risks include competitive pressures from new payment technologies and regulatory scrutiny. The stock offers upside potential but requires monitoring of valuation and market shifts.

Novavax Inc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About MasterCard Inc

Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.

Read more on MA

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX